OTCEquity is a premier site for updated news and financial information regarding penny stocks and small cap companies. We offer a free newsletter, articles about penny stock trading, otc bulletin board analytical data and original news stories about the penny stock companies you are interested in.

Registration to our newsletter is FREE, Join today by entering your email below!

Tag Archives: clinical trial

Can Itonis, Inc. (PINKSHEETS: ITNS) Bring Over-the-Counter and Prescription Homeopathic Nasal Spray for the Treatment of Nausea to Market?

Itonis, Inc. (PINKSHEETS: ITNS) has put together their second straight day of heavy trading volume following Monday’s announcement that Itonis Pharmaceuticals, a division of ITNS, had commenced the organization of the first clinical trial of their recently announced over-the-counter and … Continue reading

Posted in Uncategorized | Tagged , , , , , , , , | Leave a comment

Is PolyMedix, Inc. (OTCBB: PYMX) Playing a Familiar Song with Positive Outlook for Brilacidin?

For those investors who have held or are currently holding shares of PolyMedix, Inc. (OTCBB: PYMX) the old proverb “Fool me once shame on you. Fool me twice shame on me” may serve as a valuable reminder that the biotechnology … Continue reading

Posted in Uncategorized | Tagged , , , , , , , , , | Leave a comment

Exelixis, Inc. (NASDAQ: EXEL) Remains a Big Risk Big Reward Biotech with Everything Riding on Cancer Drug Cabozantinib

It’s possible that the climb back north may have started for Exelixis, Inc. (NASDAQ: EXEL) as the biotechnology company is now in recovery mode following yesterday’s poor performance. On Wednesday shares of EXEL sank as low as  4.27 as investors … Continue reading

Posted in Articles, NASDAQ | Tagged , , , , , , , , , , | Leave a comment

Viral Genetics Inc. (PINKSHEETS: VRAL) Advancing from Preclinical to Clinical-Stage Company with Potential Ovarian Cancer Treatment Developed from MDT Platform

One day after Viral Genetics Inc. (PINKSHEETS: VRAL) announced that the physician-initiated Investigational New Drug (P-IND) application submitted to the FDA in late April, 2012 had cleared the FDA’s screening process, paving the way for the small biotechnology company to … Continue reading

Posted in Uncategorized | Tagged , , , , , , , , , | Leave a comment

CEL-SCI Corporation Inching Closer Toward Phase III Clinical Trial of Multikine but Investors Remain Skeptical

It’s hard to image a biotechnology company entering a Phase III clinical trial to test an immunotherapy for head and neck cancer would be trading in the 0.68 – 0.71 range but that is exactly where CEL-SCI Corporation (AMEX: CVM) … Continue reading

Posted in AMEX, Articles | Tagged , , , , , , , , , , | Leave a comment